15028 results for "cancer studies using rna-seq"

in 26.31 milliseconds.

• WGS

  Our cohort represents infants with ALL in whom KMT2Ar was not detected by FISH or by standard cytogenetics. Whole-genome sequencing (WGS) was performed using Illumina’s HiSeqX to a depth of >30X.

  Dataset EGAD50000000594

• WGS data of multiple myeloma

  Dataset containing WGS data from 4 patients with 17 samples with multiple myeloma. The sequencing was always paired and performed using Illumina NovaSeq 6000

  Dataset EGAD50000000437

• GCAT| SNParray coreSpain V3 TopMed

  4988 samples issued from GCAT cohort, genotyped with MEGAex-Infinium Array, with data for Cr1-23. Plink files with QC and imputed using TOPMed r2.

  Dataset EGAD00010002749

• Methylation profiling of CDS and ES tumor samples

  Methylation profiling of 9 CDS and ES tumor samples, using the approach described in "Patient-derived tumoroids from CIC::DUX4 rearranged sarcoma identify MCL1 as a therapeutic target

  Dataset EGAD00010002760

• Single Cell-Derived chemoradiotherapy-treated colonies.

  60X WGS of single cell-derived colonies of DHL4 cells treated with platinum or RT (or unexposed control). 16 bam files aligned using MGP1000 pipeline (GRCh38).

  Dataset EGAD50000001461

• GCAT| SNParray GSA TopMed

  2746 samples issued from GCAT cohort, genotyped with GSA Array, with data for Cr1-23. Plink files with QC and imputed using TOPMed.

  Dataset EGAD00010002758

• WES of Multiple myeloma/MGUS cases (germline) - Fastq files

  WXS - Exome capture using the Twist Human Core Exome Kit on germline DNA, paired-end (2x100bp) sequencing on a NovaSeq system. Number of samples: 295

  Dataset EGAD50000001799

• HICHIP_TALL_t_14_16_translocation

  For patient P01, HiChIP experiment for was performed using the Arima-HiC+ kit (A510008, Arima genomics) according to the manufacturer’s protocols.

  Dataset EGAD50000002167

• Somatic MT SNV calls

  Filtered somatic MT SNV (heteroplasmy) calls detected using mitoCaller (v1.0)

  Dataset EGAD00001007871

• Cell line sequencing data

  SmMIP libraries using bulk cell line DNA and DNA mixes were generated in replicates and were sequenced on the NovaSeq SP platform (Illumina)

  Dataset EGAD00001007790

• Mucoepidermoid Carcinoma

  Whole exome sequencing data for 18 mucoepidermoid carcinoma samples. The samples were used for Illumina TruSeq library construction and captured using Agilent V4 exome panel. The PE fastq files are provided.

  Dataset EGAD00001003958

• Mucoepidermoid carcinoma- normals

  Whole exome sequencing data for 18 mucoepidermoid carcinoma samples. The samples were used for Illumina TruSeq library construction and captured using Agilent V4 exome panel. The PE fastq files are provided.

  Dataset EGAD00001004946

• Endometriosis

  Whole exome sequencing data for matched normal and endometriosis samples. Samples were prepared using Agilent Sureselect capture kit, and sequenced on an Illumina HiSeq 2500. The submitted files are in BAM format.

  Dataset EGAD00001004964

• Whole genome sequencing of chronic lymphocytic leukemia

  Whole genome sequencing of chronic lymphocytic leukemia, 49 CLL/control pairs, sequenced on HiSeq X Ten with DNA prepared using Illumina TruSeq DNA Nano.

  Dataset EGAD00001009638

• Live slow-frozen human tumor tissues scRNA

  Bam files of 17 samples from 11 different patients. The scRNAseq data were obtained using the 10X 3' Gene Expression kit.

  Dataset EGAD00001009284

• Homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional tissue-based immunofluorescence assays

  - WES files from primary or metastatic prostate cancer biopsies, from patients with metastatic prostate cancer. - This dataset includes those cases profiled by WES and included in the manuscript Homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional tissue-based immunofluorescence assays, Arce-Gallego et al, Cell Rep Med 2024 - The dataset includes WES for 80 tumor biopsies from 65 different patients, including paired tumor/normal samples.

  Dataset EGAD50000001018

• Cancer and germline exomes consisting of FASTQ reads from melanoma, lung and colon cancer samples

  Cancer and germline exomes consisting of FASTQ reads from 6 individuals (4 melanoma, 1 lung and 1 colon cancer). Exome sequencing was performed on illumina with a depth of 100x to 200x. 2 Melanoma datasets contain reads from 2 different tumor regions 2 Melanoma datasets contain reads from 1 tumor region and from a tumor derived cell line 1 Melanoma dataset contains reads from 2 healthy tissues Colon and lung datasets contain both 1 matched germline-tumor pair

  Dataset EGAD00001007950

• Comparison of HCC cell lines and primary HCCs

  There are concerns about whether cancer cell lines could faithfully represent the matched primary cancer cells. Comparison of the HCC cell lines and primary HCCs demonstrated that, during long-term in vitro culture, cell lines retain the genetic landscape of the matched primary HCCs.

  Study EGAS00001001678

• Genetic Risk for Subsequent Neoplasms among Long-term Survivors of Childhood Cancer in the St. Jude Lifetime Cohort

  While childhood cancer survivors are known to be at increased risk of subsequent neoplasms (SNs), the contribution of germline mutations in cancer predisposition genes to the risk of SN is largely unknown. Whole-genome sequencing (30X) was performed on 3,006 5+ year survivors of childhood cancer (median age, 35.8 [range: 7.1-69.8] years) from the St. Jude Lifetime Cohort. Survivors underwent a comprehensive clinical assessment. Germline mutations in 156 cancer predisposition genes (SJCPG156), including a subset of 60 (SJCPG60) autosomal dominant genes with moderate to high penetrance, were classified for their pathogenicity. Piecewise exponential regression, stratified by radiation exposure, was used to evaluate the relative rate (RR) and 95% confidence interval (95% CI) of SN occurrence by mutation status. Pathogenic or likely pathogenic mutations in SJCPG156 and SJCPG60 were identified in 11.7% and 5.8% of survivors, respectively. The most frequently mutated SJCPG60 genes included RB1 (n=43), NF1 (n=22), BRCA2 (n=14), BRCA1 (n=12) and TP53 (n=10). Mutations in SJCPG60 were associated with the rate of subsequent sarcoma (RR, 10.3; 95% CI, 4.2 to 25.6) and breast cancer (RR, 13.3; 95% CI, 5.8 to 30.5) among irradiated survivors, and the rate of developing any SN (RR, 4.8; 95% CI, 2.4 to 9.4) and breast cancer (RR, 7.8; 95% CI, 2.5 to 24.0) among non-irradiated survivors. The rate of developing ≥2 histologically distinct SNs was increased 17.8-fold (95% CI, 3.5 to 89.8) among SJCPG60 mutation carriers treated without radiotherapy. Similar but attenuated associations were observed for mutations in SJCPG156. Survivors who develop a SN without prior radiotherapy or who are diagnosed with a subsequent sarcoma or breast cancer within a site of prior radiotherapy should be referred to genetic counseling.

  Study EGAS00001002499

• Matched Ovarian Cancer Sequencing

  Matched Ovarian Cancer Sequencing

  Dataset EGAD00001000084

• ER-, HER2-, PR- breast Cancer genome sequencing

  ER-, HER2-, PR- breast Cancer genome sequencing

  Dataset EGAD00001000088

• Breast Cancer Exome Resequencing

  Breast Cancer Exome Resequencing

  Dataset EGAD00001000093

• Cancer Genome Libraries Tests

  Cancer Genome Libraries Tests

  Dataset EGAD00001000094

• Triple Negative Breast Cancer Whole Genomes

  Triple Negative Breast Cancer Whole Genomes

  Dataset EGAD00001000141

• SNP array datas of Matched cancer-PNE

  SNP array datas of Matched cancer-PNE

  Dataset EGAD00010001631